Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Publisher: La Merie Publishing
Pages: 223
Format: PDF
Product Line:
Target Pipeline
Product Line:
Competitor Analysis
Product Code: LMCA0173
Release Date: June of 2018

1,350.00 €
(Discount: 40.00%)
810.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:

  • Melanoma-associated antigen A: MAGE-A
  • New York esophageal squamous cell carcinoma-1: NY-ESO-1
  • Human telomerase reverse transcriptase: hTERT
  • Wilms‘ tumor 1: WT1
  • Preferentially expressed antigen in melanoma: PRAME
  • Survivin

This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets. The original reports were published in May and June 2018, respectively:

Detailed report descriptions and tables of contents from the reports can be found on the respective product page. The reports can be acquired separately or as a package with a 40%  discount on list prices.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

Tables of Contents

Competitor Analysis: MAGE-A-Targeted Immunotherapy
1)   MAGE-A-Targeted Immunotherapy:

  • MAGE-A1
  • MAGE-A3
  • MAGE-A4
  • MAGE-A6
  • MAGE-A10
  • MAGE-A12

2)        Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
1)        NY-ESO-1-Targeted Immunotherapy

  • NY-ESO-1 Selective Cancer Vaccines
  • NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  • NY-ESO-1 Selective Adoptive Cell Therapy
  • NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  • NY-ESO-1 Selective Recombinant Antibodies & Proteins

2)        Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines

Competitor Analysis: hTERT-Targeted Immunotherapy
1)        hTERT-Targeted Immunotherapy

  • hTERT-Selective Cancer Vaccines
  • hTERT-Specific, Multi-Target Cancer Vaccines
  • hTERT-Targeted Adoptive Cell Therapy 
  • Other hTERT-Targeted Immunotherapies  

2)        Corporate & Institutional hTERT Immunotherapy R&D Pipelines

Competitor Analysis: WT1-Targeted Immunotherapy
1)        WT1-Targeted Immunotherapy

  • Selective WT1-Targeted Vaccines
  • WT1-Specific, Multi-Target Vaccines
  • WT1-Selective Adoptive Cell Therapy
  • WT1-Specific, Multi-Target Adoptive Cell Therapy
  • WT1-Targeted Antibodies

2)        Corporate & Institutional WT1 Immunotherapy R&D Pipelines

Competitor Analysis: PRAME-Targeted Immunotherapy
1)        PRAME-Targeted Immunotherapy

  • PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
  • PRAME-Selective Cellular & Recombinant Immunotherapies
  • PRAME-Specific, Multi-Target Adoptive Cell Therapy

2)        Corporate & Insitutional PRAME Immunotherapy R&D Pipelines

Competitor Analysis: Survivin-Targeted Immunotherapy
1)        Survivin-Targeted Immunotherapy

  • Survivin-Selective Cancer Vaccines
  • Survivin-Specific, Multi-Antigen Cancer Vaccines
  • Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
  • Survivin-Specific, Multi-Target Adoptive T-Cell Therapy

2)        Corporate Survivin Immunotherapy R&D Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up